Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023
|
EQS-Ad-hoc: Epigenomics AG / Key word(s): Contract/Disposal Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023 Berlin, Germany, October 10, 2023 – Epigenomics AG (Frankfurt General Standard: ECX1; the “Company”) closed today the agreement entered into on July 24, 2023 with New Day Diagnostics LLC (“New Day Diagnostics”), a U.S.-based diagnostics and contract research company, for the sale of its major assets. As a result, almost all of the Company's assets have been transferred to New Day Diagnostics. As part of the closing, the Company has received as consideration a cash payment of USD 0.5 million and an interest in New Day Diagnostics. Furthermore, the Company is entitled to payments in the amount of USD 1.0 million as of December 1, 2023 and further USD 0.3 million as of June 30, 2024. The agreement with New Day Diagnostics provides for further potential cash payments. These payments depend, for one thing, on the achievement of certain milestones related to Epi proColon and in particular Epi proColon “Next-Gen” and can amount to up to USD 8.0 million. On the other hand, the Company is eligible for license payments and earn-out payments (mainly in the form of royalties on sales) in the period until 2043, the end of the patent lifetime, which are dependent on the commercialization of Epi proColon “Next-Gen”. As a consequence of the closing of the agreement with New Day Diagnostics, the Company has adjusted its guidance for 2023 and now expects an adjusted EBITDA (before share-based payment expenses) in a range of EUR -4.5 million to EUR -5.5 million (previously EUR -7.0 million to EUR -9.0 million). The adjustment results essentially from the income for the year 2023 from the contract with New Day Diagnostics. The expected cash-consumption for 2023 of EUR 7.0 million to EUR 9.0 million remains unchanged.
Contact: Investor Relations
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise. End of Inside Information
10-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Epigenomics AG |
| Bertha-Benz-Straße 5 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A32VN83 |
| WKN: | A32VN8 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1745803 |
| End of Announcement | EQS News Service |
|
|
1745803 10-Oct-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.